Answer: Retatrutide trials focus on adults with obesity or overweight, typically a BMI at or above 27, who also carry a weight-related condition such as type 2 diabetes, pre-diabetes, high blood pressure, or high cholesterol
Reduction of cardiovascular risk and improved estimated glomerular filtration rate by SGLT2 inhibitors, including dapagliflozin, is consistent across the class: an analysis of the placebo arm of EXSCEL
However, further trials with larger and various population and longer follow-up are needed
At designated time intervals, 10 L of CCK-8 solution was added to each well, followed by incubation for 2 h
They represent the first time in the pharmacological history of obesity treatment that a drug trial has produced bariatric-surgery-level weight reduction at this scale, across 2,339 participants